Illumina, Inc. ILMN
$158.98▼ -3.15% 24H
Super Investor & Insider
2
Fondi che lo detengono
#520
Rank consenso
2.9%
% dei portafogli
$104.9M
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| Samantha McLemore · Patient Capital Management | 2.5% | Reduce 5.38% | 544,780 | $67.1M |
| Triple Frond Partners · Triple Frond Partners | 3.92% | Reduce 18.09% | 306,460 | $37.8M |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Illumina, Inc. is a life sciences and diagnostics company that develops, manufactures, and markets tools and integrated systems for the analysis of genetic material. Its primary focus is on next-generation sequencing technologies, providing high-throughput and lower-throughput sequencing instruments, consumables, and r…
SectorHealthcare
ExchangeNASDAQ
IndustryDiagnostics & Research
CountryUnited States
Employees8,600
TickerILMN
Statistics
Market Cap$24.16B
Revenue (TTM)$4.34B
Net Income$850.0M
Net Margin19.6%
EPS$5.45
P/E30.17
P/S5.72
P/B9.44
EV/EBITDA22.48
ROE33.8%
Dividend Yield—
Price$158.98
Data: Twelve Data · Revenue = mcap / P/S